After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology

In the CAPItello281 trial, survival results with capivasertib plus abiraterone are promising, but questions remain on the accurate determination of PTEN loss in patients 

Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types

Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability

Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting

While a HER2-targeted bispecific antibody showed extended survival in pre-treated gastric cancers, TKI–immunotherapy combinations failed to confer a survival benefit

Follow-up data at 7 and 5 years from monarchE and NATALEE provide reassurance of the sustained benefits of adjuvant CDK4/6 inhibitors in improving survival and reducing relapse

In a phase III trial, lower doses of adjuvant radiotherapy plus docetaxel were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy, with an impact on quality of life 

Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed

Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment